サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413152

非侵襲性リキッドバイオプシー市場：タイプ、技術、エンドユーザー別-2024-2030年の世界予測

Non-Invasive Liquid Biopsy Market by Type (Assay Kits, Instruments, Services), Technology (Next Generation Sequencing (NGS), RT-PCR and dPCR), End-user - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
非侵襲性リキッドバイオプシー市場：タイプ、技術、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非侵襲性リキッドバイオプシー市場規模は2023年に10億1,000万米ドルと推計され、2024年には11億9,000万米ドルに達し、CAGR 18.10%で2030年には32億5,000万米ドルに達すると予測されます。

世界の非侵襲性リキッドバイオプシー市場

主な市場の統計
基準年[2023］ 10億1,000万米ドル
予測年[2024］ 11億9,000万米ドル
予測年 [2030] 32億5,000万米ドル
CAGR（%） 18.1%
非侵襲性リキッドバイオプシー Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは非侵襲性リキッドバイオプシー市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、非侵襲性リキッドバイオプシー市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-非侵襲性リキッドバイオプシー市場の市場規模および予測は？

2-非侵襲性リキッドバイオプシー市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-非侵襲性リキッドバイオプシー市場における技術動向と規制の枠組みは？

4-非侵襲性リキッドバイオプシー市場における主要ベンダーの市場シェアは？

5-非侵襲性リキッドバイオプシー市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • がんの発生率と有病率の上昇
      • 非侵襲的診断手順に対する嗜好の増加
    • 抑制要因
      • 高度な非侵襲性リキッドバイオプシーに伴う高コスト
    • 機会
      • 人工知能と非侵襲性リキッドバイオプシーの統合
      • 先進的なヘルスケアインフラへの投資の増加
    • 課題
      • さまざまな技術や腫瘍の種類にわたる標準化の欠如
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 非侵襲性リキッドバイオプシー市場：タイプ別

  • アッセイキット
  • 機器
  • サービス

第7章 非侵襲性リキッドバイオプシー市場：技術別

  • 次世代シーケンシング（NGS）
  • RT-PCRおよびdPCR

第8章 非侵襲性リキッドバイオプシー市場：エンドユーザー別

  • 学術研究センター
  • 臨床診断研究所
  • 病院

第9章 南北アメリカの非侵襲性リキッドバイオプシー市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の非侵襲性リキッドバイオプシー市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの非侵襲性リキッドバイオプシー市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Angle PLC
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • Biocept, Inc.
    • DiaCarta, Inc.
    • Epic Sciences Inc.
    • F. Hoffmann-La Roche Ltd.
    • Guardant Health, Inc.
    • Illumina, Inc.
    • Integrated DNA Technologies, Inc.
    • Laboratory Corporation of America Holdings
    • Lonza Group Ltd.
    • Lucence Diagnostics Pte. Ltd.
    • LungLife AI, Inc.
    • Mdxhealth BV
    • MedGenome Labs Ltd.
    • Menarini Silicon Biosystems SpA
    • Merck KGaA
    • Nonacus Limited
    • Norgen Biotek Corporation
    • Oasis Diagnostics Corporation
    • OraSure Technologies, Inc
    • QIAGEN GmbH
    • Thermo Fisher Scientific Inc.
    • Zymo Research Corp.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. NON-INVASIVE LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NON-INVASIVE LIQUID BIOPSY MARKET DYNAMICS
  • FIGURE 7. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. NON-INVASIVE LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 10. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RT-PCR AND DPCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. NON-INVASIVE LIQUID BIOPSY MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5B054

[185 Pages Report] The Non-Invasive Liquid Biopsy Market size was estimated at USD 1.01 billion in 2023 and expected to reach USD 1.19 billion in 2024, at a CAGR 18.10% to reach USD 3.25 billion by 2030.

Global Non-Invasive Liquid Biopsy Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.19 billion
Forecast Year [2030] USD 3.25 billion
CAGR (%) 18.1%
Non-Invasive Liquid Biopsy Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Non-Invasive Liquid Biopsy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Non-Invasive Liquid Biopsy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Non-Invasive Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocept, Inc., DiaCarta, Inc., Epic Sciences Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Lucence Diagnostics Pte. Ltd., LungLife AI, Inc., Mdxhealth BV, MedGenome Labs Ltd., Menarini Silicon Biosystems SpA, Merck KGaA, Nonacus Limited, Norgen Biotek Corporation, Oasis Diagnostics Corporation, OraSure Technologies, Inc, QIAGEN GmbH, Thermo Fisher Scientific Inc., and Zymo Research Corp..

Market Segmentation & Coverage

This research report categorizes the Non-Invasive Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Assay Kits
    • Instruments
    • Services
  • Technology
    • Next Generation Sequencing (NGS)
    • RT-PCR and dPCR
  • End-user
    • Academic & Research Centers
    • Clinical Diagnostic Laboratories
    • Hospital
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Non-Invasive Liquid Biopsy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Non-Invasive Liquid Biopsy Market?

3. What are the technology trends and regulatory frameworks in the Non-Invasive Liquid Biopsy Market?

4. What is the market share of the leading vendors in the Non-Invasive Liquid Biopsy Market?

5. Which modes and strategic moves are suitable for entering the Non-Invasive Liquid Biopsy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Non-Invasive Liquid Biopsy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and prevalence of cancer
      • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced non-invasive liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence with non-invasive liquid biopsy
      • 5.1.3.2. Increasing investment for advanced healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization across different techniques and tumor types
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Non-Invasive Liquid Biopsy Market, by Type

  • 6.1. Introduction
  • 6.2. Assay Kits
  • 6.3. Instruments
  • 6.4. Services

7. Non-Invasive Liquid Biopsy Market, by Technology

  • 7.1. Introduction
  • 7.2. Next Generation Sequencing (NGS)
  • 7.3. RT-PCR and dPCR

8. Non-Invasive Liquid Biopsy Market, by End-user

  • 8.1. Introduction
  • 8.2. Academic & Research Centers
  • 8.3. Clinical Diagnostic Laboratories
  • 8.4. Hospital

9. Americas Non-Invasive Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Non-Invasive Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Non-Invasive Liquid Biopsy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Angle PLC
    • 13.1.2. Bio-Rad Laboratories, Inc.
    • 13.1.3. Bio-Techne Corporation
    • 13.1.4. Biocept, Inc.
    • 13.1.5. DiaCarta, Inc.
    • 13.1.6. Epic Sciences Inc.
    • 13.1.7. F. Hoffmann-La Roche Ltd.
    • 13.1.8. Guardant Health, Inc.
    • 13.1.9. Illumina, Inc.
    • 13.1.10. Integrated DNA Technologies, Inc.
    • 13.1.11. Laboratory Corporation of America Holdings
    • 13.1.12. Lonza Group Ltd.
    • 13.1.13. Lucence Diagnostics Pte. Ltd.
    • 13.1.14. LungLife AI, Inc.
    • 13.1.15. Mdxhealth BV
    • 13.1.16. MedGenome Labs Ltd.
    • 13.1.17. Menarini Silicon Biosystems SpA
    • 13.1.18. Merck KGaA
    • 13.1.19. Nonacus Limited
    • 13.1.20. Norgen Biotek Corporation
    • 13.1.21. Oasis Diagnostics Corporation
    • 13.1.22. OraSure Technologies, Inc
    • 13.1.23. QIAGEN GmbH
    • 13.1.24. Thermo Fisher Scientific Inc.
    • 13.1.25. Zymo Research Corp.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing